Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Shares in Ironwood Pharmaceuticals ($IRWD), which creates and sells medicines for people with severe stomach and digestive ...

Check out a month-by-month breakdown of the major events affecting the pharma and medical marketing industries in 2025.

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

It’s been another whirlwind year in the world of pharma marketing. | Updates on DTC advertising and DTP programs, as well as special reports, event coverage and, of course, news bulletins from the ...

The year also reinforced a long-standing strength of Indian pharma: its ability to scale through strategic consolidation.

Asahi Kasei Pharma Corporation has announced plans to relocate its R&D hub from Izunokuni City, Shizuoka Prefecture (Ohito) ...

Dec 24 (Reuters) - Shares of Agios ‌Pharmaceuticals ​jumped nearly 12% premarket ‌on Wednesday after the U.S. Food ​and Drug Administration approved the expanded use of its drug ‍for the treatment of ...